IRCT20210620051639N2 IRCT 2021-10-11 Bagheiat-allah University of Medical Sciences Clinical trial of Noora vaccine A double-blind, randomized, placebo-controlled Phase II clinical trial to evaluate the immunogenicity and safety of covid-19 recombinant RBD protein vaccine (80 microgram) of Plasma Darman Sarve Sepid Co. in healthy population. 2021-10-12 anticipated 300 Complete https://irct.ir/trial/59156 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: The randomization process in this study will be done in one step and a random chain will be created. For this purpose, 72 random block sequences with size 5 are produced so that for every 4 volunteers receiving active vaccine, 1 volunteer will receive a placebo, Blinding description: Each dose of vaccine is packaged separately and has an identification number. Vaccine boxes and placebo are offered in exactly the same appearance and packaging, which will blind the participants, researchers and outcome assessors. After using the vaccine, the abbreviation of the study participant and the date of vaccination are written in the outer packaging box and the activity label is recorded on the main sheet. Personnel check all information before injection. During the study, all outer packing boxes will be archived and maintained. 2 COVID-19. Intervention 1: Intervention group: receiving 80 micrograms of RBD protein recombinant SARS-CoV-2 vaccine in days 0, 21, and 35; intramuscular (deltoid muscle). Intervention 2: Control group: the placebo group will receive an intramuscular injection (in the deltoid muscle) consisting of buffer and adjuvant only, on days 0, 21, and 35. No - There is not a plan to make this available Justification or reason for not sharing IPD is No plans to release patient data